Clinical Trial

Effect of an Polyphenolic Beverage in Healthy Volunteers

Study acronym: PB
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Currently, there are different strategies to prevent the effect of beverages and foods on blood glucose levels after ingestion. In this sense, polyphenols are a promising field; these compounds are secondary metabolites produced by plants, vegetables, and fruits; of these compounds, gallic acid, quercetin, and kaempferol stand out for their antihyperglycemic characteristics through a) complex formation, b) enzymatic inhibition, c) affecting transport and, d) stimulation of the secretion of intestinal satiety hormones. Vachellia farnesiana (VF) is a shrub distributed in arid, semi-arid, and tropical regions of Mexico and the world. The polyphenols of the fruits of VF in pre-clinical studies by this research group have shown important antioxidant activity and antihyperglycemic effects. The present proposal aims to evaluate the effect of the polyphenolic extract of Vachellia farnesiana on glycemic response and to monitor liver and renal function tests as a safety control in healthy volunteers through developing a Phase I clinical study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-27.
Status change: Withdrawn → Active, Not Recruiting 2025-05-08
Trial Details
NCT Number NCT05802472
Lead Sponsor Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions Healthy, Safety Issues
Enrollment 60 participants
Start Date 2022-04-06
Primary Completion 2025-10-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-13